570 related articles for article (PubMed ID: 27648814)
21. Clinical activity of enzalutamide in Docetaxel-naïve and Docetaxel-pretreated patients with metastatic castration-resistant prostate cancer.
Nadal R; Zhang Z; Rahman H; Schweizer MT; Denmeade SR; Paller CJ; Carducci MA; Eisenberger MA; Antonarakis ES
Prostate; 2014 Nov; 74(15):1560-8. PubMed ID: 25176007
[TBL] [Abstract][Full Text] [Related]
22. Androgen Receptor Modulation Optimized for Response-Splice Variant: A Phase 3, Randomized Trial of Galeterone Versus Enzalutamide in Androgen Receptor Splice Variant-7-expressing Metastatic Castration-resistant Prostate Cancer.
Taplin ME; Antonarakis ES; Ferrante KJ; Horgan K; Blumenstein B; Saad F; Luo J; de Bono JS
Eur Urol; 2019 Dec; 76(6):843-851. PubMed ID: 31542304
[TBL] [Abstract][Full Text] [Related]
23. Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Extended Analysis of the Phase 3 PREVAIL Study.
Beer TM; Armstrong AJ; Rathkopf D; Loriot Y; Sternberg CN; Higano CS; Iversen P; Evans CP; Kim CS; Kimura G; Miller K; Saad F; Bjartell AS; Borre M; Mulders P; Tammela TL; Parli T; Sari S; van Os S; Theeuwes A; Tombal B
Eur Urol; 2017 Feb; 71(2):151-154. PubMed ID: 27477525
[TBL] [Abstract][Full Text] [Related]
24. U.S. Food and Drug Administration Approval Summary: Enzalutamide for the Treatment of Patients With Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer.
Ning YM; Brave M; Maher VE; Zhang L; Tang S; Sridhara R; Kim G; Ibrahim A; Pazdur R
Oncologist; 2015 Aug; 20(8):960-6. PubMed ID: 26070917
[TBL] [Abstract][Full Text] [Related]
25. [Enzalutamide-a novel androgen receptor inhibitor that provides treatment options for patients with castration-resistant prostate cancer].
Maeda H; Saito A
Gan To Kagaku Ryoho; 2014 Jul; 41(7):805-10. PubMed ID: 25131864
[TBL] [Abstract][Full Text] [Related]
26. Enzalutamide in Japanese patients with chemotherapy-naïve, metastatic castration-resistant prostate cancer: A post-hoc analysis of the placebo-controlled PREVAIL trial.
Kimura G; Yonese J; Fukagai T; Kamba T; Nishimura K; Nozawa M; Mansbach H; Theeuwes A; Beer TM; Tombal B; Ueda T
Int J Urol; 2016 May; 23(5):395-403. PubMed ID: 27018069
[TBL] [Abstract][Full Text] [Related]
27. Enzalutamide in Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer: An Asian Multiregional, Randomized Study.
Pu YS; Ahn H; Han W; Huang SP; Wu HC; Ma L; Yamada S; Suga K; Xie LP
Adv Ther; 2022 Jun; 39(6):2641-2656. PubMed ID: 35397772
[TBL] [Abstract][Full Text] [Related]
28. Prostate-specific Antigen Progression in Enzalutamide-treated Men with Nonmetastatic Castration-resistant Prostate Cancer: Any Rise in Prostate-specific Antigen May Require Closer Monitoring.
Saad F; Sternberg CN; Efstathiou E; Fizazi K; Modelska K; Lin X; Sugg J; Steinberg J; Noerby B; Shore ND; Hussain M
Eur Urol; 2020 Dec; 78(6):847-853. PubMed ID: 33010985
[TBL] [Abstract][Full Text] [Related]
29. Efficacy and Safety of Enzalutamide vs Bicalutamide in Younger and Older Patients with Metastatic Castration Resistant Prostate Cancer in the TERRAIN Trial.
Siemens DR; Klotz L; Heidenreich A; Chowdhury S; Villers A; Baron B; van Os S; Hasabou N; Wang F; Lin P; Shore ND
J Urol; 2018 Jan; 199(1):147-154. PubMed ID: 28827103
[TBL] [Abstract][Full Text] [Related]
30. Radiographic progression with nonrising PSA in metastatic castration-resistant prostate cancer: post hoc analysis of PREVAIL.
Bryce AH; Alumkal JJ; Armstrong A; Higano CS; Iversen P; Sternberg CN; Rathkopf D; Loriot Y; de Bono J; Tombal B; Abhyankar S; Lin P; Krivoshik A; Phung D; Beer TM
Prostate Cancer Prostatic Dis; 2017 Jun; 20(2):221-227. PubMed ID: 28117385
[TBL] [Abstract][Full Text] [Related]
31. Development of enzalutamide for metastatic castration-resistant prostate cancer.
Bhattacharya S; Hirmand M; Phung D; van Os S
Ann N Y Acad Sci; 2015 Nov; 1358():13-27. PubMed ID: 26384731
[TBL] [Abstract][Full Text] [Related]
32. Impact of Enzalutamide Compared with Bicalutamide on Quality of Life in Men with Metastatic Castration-resistant Prostate Cancer: Additional Analyses from the TERRAIN Randomised Clinical Trial.
Heidenreich A; Chowdhury S; Klotz L; Siemens DR; Villers A; Ivanescu C; Holmstrom S; Baron B; Wang F; Lin P; Shore ND
Eur Urol; 2017 Apr; 71(4):534-542. PubMed ID: 27497762
[TBL] [Abstract][Full Text] [Related]
33. Effect of enzalutamide on health-related quality of life, pain, and skeletal-related events in asymptomatic and minimally symptomatic, chemotherapy-naive patients with metastatic castration-resistant prostate cancer (PREVAIL): results from a randomised, phase 3 trial.
Loriot Y; Miller K; Sternberg CN; Fizazi K; De Bono JS; Chowdhury S; Higano CS; Noonberg S; Holmstrom S; Mansbach H; Perabo FG; Phung D; Ivanescu C; Skaltsa K; Beer TM; Tombal B
Lancet Oncol; 2015 May; 16(5):509-21. PubMed ID: 25888263
[TBL] [Abstract][Full Text] [Related]
34. Factors predicting efficacy and adverse effects of enzalutamide in Japanese patients with castration-resistant prostate cancer: results of retrospective multi-institutional study.
Terada N; Akamatsu S; Okada Y; Negoro H; Kobayashi T; Yamasaki T; Matsui Y; Inoue T; Kamba T; Ogawa O
Int J Clin Oncol; 2016 Dec; 21(6):1155-1161. PubMed ID: 27351872
[TBL] [Abstract][Full Text] [Related]
35. Efficacy and safety of enzalutamide versus bicalutamide for patients with metastatic prostate cancer (TERRAIN): a randomised, double-blind, phase 2 study.
Shore ND; Chowdhury S; Villers A; Klotz L; Siemens DR; Phung D; van Os S; Hasabou N; Wang F; Bhattacharya S; Heidenreich A
Lancet Oncol; 2016 Feb; 17(2):153-163. PubMed ID: 26774508
[TBL] [Abstract][Full Text] [Related]
36. Statin and metformin use and outcomes in patients with castration-resistant prostate cancer treated with enzalutamide: A meta-analysis of AFFIRM, PREVAIL and PROSPER.
Joshua AM; Armstrong A; Crumbaker M; Scher HI; de Bono J; Tombal B; Hussain M; Sternberg CN; Gillessen S; Carles J; Fizazi K; Lin P; Duggan W; Sugg J; Russell D; Beer TM
Eur J Cancer; 2022 Jul; 170():285-295. PubMed ID: 35643841
[TBL] [Abstract][Full Text] [Related]
37. Enzalutamide versus flutamide for castration-resistant prostate cancer after combined androgen blockade therapy with bicalutamide: a retrospective study.
Iguchi T; Tamada S; Kato M; Yasuda S; Otoshi T; Hamada K; Yamasaki T; Nakatani T
Int J Clin Oncol; 2019 Jul; 24(7):848-856. PubMed ID: 30741370
[TBL] [Abstract][Full Text] [Related]
38. Efficacy of Enzalutamide plus Androgen Deprivation Therapy in Metastatic Hormone-Sensitive Prostate Cancer by Pattern of Metastatic Spread: ARCHES Post Hoc Analyses.
Armstrong AJ; Shore ND; Szmulewitz RZ; Petrylak DP; Holzbeierlein J; Villers A; Azad A; Alcaraz A; Alekseev B; Iguchi T; Gomez-Veiga F; Rosbrook B; Lee HJ; Haas GP; Stenzl A
J Urol; 2021 May; 205(5):1361-1371. PubMed ID: 33356529
[TBL] [Abstract][Full Text] [Related]
39. The Effect of Corticosteroids on Prostate Cancer Outcome Following Treatment with Enzalutamide: A Multivariate Analysis of the Phase III AFFIRM Trial.
Zhao JL; Fizazi K; Saad F; Chi KN; Taplin ME; Sternberg CN; Armstrong AJ; de Bono JS; Duggan WT; Scher HI
Clin Cancer Res; 2022 Mar; 28(5):860-869. PubMed ID: 34965947
[TBL] [Abstract][Full Text] [Related]
40. Safety and effectiveness of enzalutamide in men with metastatic, castration-resistant prostate cancer.
Graff JN; Gordon MJ; Beer TM
Expert Opin Pharmacother; 2015 Apr; 16(5):749-54. PubMed ID: 25687355
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
